COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, to advance proteome and proteogenome science and technology development through community resources (data and reagents), and to accelerate the translation of molecular findings into the clinic. This is achieved through extramural programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, collaborations with international organizations/institutions, and intramural reference laboratories such as the Antibody Characterization Lab and Clinical Proteomic Characterization Lab.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

News and Announcements

September 14, 2017
Oral Squamous Cell Carcinoma Mutational Profile in Taiwanese Population

Oral squamous cell carcinoma (OSCC) is a major oral cancer subtype that is the fourth most common cancer affecting Taiwanese men. Despite known risk behaviors such as cigarette smoking, alcohol drinking, and betel nut chewing often indulged by Taiwanese men, the genetic contribution to the incidence...
September 6, 2017
47th Vice President of the United States Joseph R. Biden, Jr. to deliver keynote address at HUPO2017 Global Leadership Gala Dinner

The Human Proteome Organization (HUPO) and Prof Steve Pennington, UCD, chair of the organizing committee of HUPO2017 (the 16th HUPO World Congress) in...
August 9, 2017
CPTAC Collaborates with Molecular & Cellular Proteomics to Address Reproducibility in Targeted Assay Development

The journal Molecular & Cellular Proteomics (MCP), in collaboration with the Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI), part of the National Institutes of Health, announce new guidelines and requirements for papers describing the development and...
July 25, 2017
CPTAC Team Releases Targeted Proteomic Assays for Ovarian Cancer

Pacific Northwest National Laboratory (PNNL) investigators in the Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI), announces the public release of 98 targeted mass spectrometry-based assays for ovarian cancer research studies.  Chosen based on proteogenomic...
July 18, 2017
NCI and FDA to Study Cancer Proteogenomics Together

The National Cancer Institute (NCI) Office of Cancer Clinical Proteomics Research (OCCPR), part of the National Institutes of Health, and the U.S. Food and Drug Administration (FDA) has signed a Memorandum of Understanding (MOU) in proteogenomic regulatory science.  This will allow the agencies to...
July 6, 2017
Announcing the Launch of CPTAC’s Proteogenomics DREAM Challenge

This week, we are excited to announce the launch of the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Proteogenomics Computational DREAM Challenge.  The aim of this Challenge is to encourage the generation of computational methods for extracting information from the...
July 5, 2017
VIDEO: Dr. Henry Rodriguez - Proteogenomics in Cancer Medicine

Dr. Henry Rodriguez, director of the Office of Cancer Clinical Proteomics Research (OCCPR) at NCI, speaks with ecancer television at WIN 2017 about the translation of the proteins expressed in a patient's tumor...
June 27, 2017
CPTAC Announces New PTRCs, PCCs, and PGDACs

This week, the Office of Cancer Clinical Proteomics Research (OCCPR) at the National Cancer Institute (NCI), part of the National Institutes of Health, announced its aim to further the convergence of proteomics with genomics – “proteogenomics,” to better understand the molecular basis of cancer and...
May 8, 2017
NCI-CPTAC DREAM Proteogenomics Challenge (Registration Now Open)

Proteogenomics, integration of proteomics, genomics, and transcriptomics, is an emerging approach that promises to advance basic, translational and clinical research.  By combining genomic and proteomic information, leading scientists are gaining new insights due to a more complete and unified...
April 3, 2017
CPTAC Investigators Identify Rogue Breast Tumor Proteins That Point To Potential Drug Therapies

For patients with difficult-to-treat cancers, doctors increasingly rely on genomic testing of tumors to identify errors in the DNA that indicate a tumor can be targeted by existing therapies. But this approach overlooks another potential marker — rogue proteins — that may be driving cancer cells and...

Pages

more

View all News and Announcements

NIH…Turning Discovery Into Health®